Results 71 to 80 of about 3,759 (138)

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes, Julian Kött, Finn Abeck, Inga Hansen‐Abeck, Jana Bertels, Nina Booken, Stefan W. Schneider   +6 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Immunotargets and Therapy for Prurigo Nodularis

ImmunoTargets and Therapy, 2022
Angelina Labib, Teresa Ju, Ashley Vander Does, Gil Yosipovitch Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Gil Yosipovitch, Dr ...
Labib A, Ju T, Vander Does A, Yosipovitch G   +3 more
doaj  

Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC

Contact Dermatitis, Volume 95, Issue 1, Page 17-32, July 2026.
ABSTRACT Background Patch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re‐)assessing the diagnostic value of EBS allergens. Objectives To present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022.
Wolfgang Uter, S. Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon, Ana Giménez Arnau, Cataldo Patruno, Györgyi Pónyai, Stamatis Gregoriou, Steffen Schubert, Dagmar Simon, Luca Stingeni, Skaidra Valiukevičienė, Elke Weisshaar, Thomas Werfel, Margarida Gonçalo, Marie‐L. A. Schuttelaar, ESSCAA and EBSB ESCD Working Groups, and the GEIDACC , Birger Kränke, Alexander Navarini, Philip Spring, Ulrike Beiteke, Cecilia Dietrich, Sibylle Schliemann, Detlef Becker, Swen Malte John, Nicola Wagner, Dimitra Koumaki, Maddalena Napolitano, Anna Belloni Fortina, Francesca Larese Filon, Rosella Gallo, Thomas Rustemeyer, Radoslaw Spiewak, Maja Kalac Pandurovic, Tanja Kmecl, Mojca Simončič Godnič, Nada Kecelj, Philippa Cousen, Ella Dendooven, Juan Francisco Silvestre Salvador, José Manuel Carrascosa Carrillo, Mónica Munera Campos, Esther Serra Baldrich, Gemma Melé‐Ninot, Cristina Barrabés Torrella, David Pesqué, María Antonia Pastor Nieto, Francisco Navarro Triviño, Inmaculada Ruiz Gonzales, Enrique Gómez de la Fuente, Susana Córdoba Guijarro, Francisco Javier Ortiz de Frutos, Fátima Tous Romero, Tatiana Sanz Sánchez, Pablo Chicharro Manso, Marta Andreu Barasoain, Marta Elosua González, Araceli Sánchez Gilo, Paloma Sánchez‐Pedreño Guillén, Pedro Mercader‐García, Carmen Paredes Suárez, María Elena Gatica Ortega, José Juan Pereyra Rodríguez, Javier Miquel Miquel, Mercedes Rodríguez Serna, Violeta Zaragoza Ninet, Ricardo González Pérez   +73 more
wiley   +1 more source

Taiwanese Dermatological Association consensus for the diagnosis and management of prurigo nodularis

Dermatologica Sinica
Prurigo nodularis (PN) is a chronic neuroinflammatory skin disease that, while considered rare, is likely underestimated. Due to its complex presentation, misdiagnosis is not uncommon, highlighting the need for greater awareness among healthcare ...
Cheng-Che E. Lan, Wen-Hung Chung, Yang-Yi Chen, Pa-Fan Hsiao, Yu-Ping Hsiao, Chih-Hung Lee, Tzu-Kai Lin, Hsing-San Yang   +7 more
doaj   +1 more source

Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy.
Sanila Mughal, Roshanay Ejaz Awan, Hur Abbas, Zahra Sania, Ashna Habib, Syeda Kaneez Sakina, Amina Mahmud, Mohammed Mahmmoud Fadelallah Eljack   +7 more
wiley   +1 more source

Recent advances in treatment of prurigo nodularis

Dermatologica Sinica
Prurigo nodularis is a chronic skin condition which has significant negative impacts on the psychosocial function and quality of life of affected patients.
Chieh-Hsun Chen, Stephen Chu-Sung Hu
doaj   +1 more source

Prevalence and Burden of Somatic Symptom Disorder in Atopic Dermatitis and Chronic Pruritus—The Persistent Somatic Symptoms Across Diseases: Pruritus (SOMA.PRU) Study

JEADV Clinical Practice, Volume 5, Issue 2, Page 486-494, June 2026.
In adults with atopic dermatitis and chronic pruritus, the mental comorbidity of Somatic Symptom Disorder is associated with higher average and worst pruritus intensity, higher psychological distress and lower quality of life. Additionally, there were nonsignificant changes in cutaneous nerve fiber densities in skin biopsies.
Stefan M. Kahnert, Ansgar Koechel, Gina L. Frank, Svenja Royeck, Claudia Zeidler, Felix Witte, Christian Mess, Konstantin Agelopoulos, Volker Huck, Bernd Löwe, Rupert Conrad, Gudrun Schneider, Stefan W. Schneider, Sonja Ständer   +13 more
wiley   +1 more source

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

JEADV Clinical Practice, Volume 5, Issue 2, Page 644-647, June 2026.
ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission ...
Evangelos Christou, Sharon Edwards, Andrew Affleck   +2 more
wiley   +1 more source